|Over a month ago|
Gracell plans to expand GC012F's clinical profile, says Piper Sandler » 10:3206/1406/14/21
Piper Sandler analyst…
Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $40 price target on Gracell shares following the company's update that provided an overview of the multiple myeloma landscape, as well as GC012F's recently updated data presented at ASCO and EHA. There remains a high unmet need for high-risk MM patients, and Catanzaro says that while GC012F has reported impressive early activity in this population, Gracell anticipates pursuing r/r MM irrespective of risk category and believes that GC012F's clinical profile could look even more favorable in standard-risk patients, the analyst tells investors in a research note.
Gracell to host conference call » 07:5506/1406/14/21
Management holds a…
Gracell to host conference call » 04:5506/1406/14/21
Management holds a…
Gracell to host conference call » 15:0206/1306/13/21
Management holds a…
Gracell valuation provides attractive entry point, says Citi » 06:2506/0706/07/21
The most important data…
The most important data for Gracell Biotechnologies (GRCL) at ASCO came from competitor Bluebird Bio (BLUE), which for the first time showed subgroup data among high-risk multiple myeloma patients, Citi analyst Mohit Bansal tells investors in a research note. Bluebird showing high risk subgroup data from the prior trial helps put the Gracell data in perspective, says the analyst. Bansal continues to see a path for Gracell where the company can "leapfrog competition" in high risk first line patients and become the standard of care. This segment represents a sizable 25% market of the total myeloma market, says the analyst. He remains remain bullish on Gracell's prospects and thinks the current valuation provides an attractive entry point.
Piper sees 'clear line of sight for value creation' at Gracell after ASCO » 11:0406/0406/04/21
After Gracell presented…
After Gracell presented updated long-term follow-up data and data on additional patients treated with GC012F, a dual-targeted "FasTCAR" therapy, at ASCO, Piper Sandler analyst Joseph Catanzaro said the data provide "further validation" for the company's FasTCAR platform. The analyst, who views GC012F's early clinical profile as comparing "very favorably" to other anti-BCMA CAR programs, said he sees a "clear line of sight for value creation" at Gracell coming out of the medical meeting. He keeps an Overweight rating on Gracell with a $40 price target on the shares.
Gracell reschedules clinical update conference call » 08:5006/0206/02/21
Gracell Biotechnologies announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2021 Virtual Congress. The conference call and webcast have been rescheduled to a time after the release of the e-poster presentation at the EHA 2021 Virtual Congress. Details for the rescheduled conference call are as follows: Monday, June 14, 2021 @ 8:00 am ET.
Gracell Biotechnologies Inc (ADS) trading resumes 13:1205/2805/28/21
Gracell Biotechnologies Inc (ADS) trading halted, volatility trading pause 13:0705/2805/28/21
Gracell reports Q1 EPS (5c), consensus (21c) » 08:0605/1705/17/21
"We are thrilled to…
"We are thrilled to have ushered in the new year as a public company following a successful initial public offering that was supported by top-tier institutional investors," commented Dr. William Cao, founder, Chairman, and CEO of Gracell. "We have made significant advancements during the first quarter regarding our pipeline of innovative autologous and allogeneic CAR-T cell therapies. Recently, we announced dosing the first patient in the Phase 1/2 registrational study of GC007g, an allogeneic CAR-T cell therapy derived from HLA-matched donors for the treatment of r/r B-ALL. At the AACR 2021 Annual Meeting last month, we presented follow-up data on our off-the-shelf stand-alone allogeneic CAR-T cell therapy GC027 for the treatment of r/r T-ALL. With a patient maintaining minimal residual disease negative complete remission through 16.8 months, we are very encouraged by the potential of GC027 in this hard-to-treat indication. We are pleased to announce that we are expanding our leadership team with Jenny Ni, Ph.D., M.D., as Chief Technology Officer. Dr. Ni brings extensive experience in developing CAR-T cell therapies, including having successfully lead process development at both Pfizer and Allogene Therapeutics. We look forward to her contributions, including leading our technical operations teams including Chemistry, Manufacturing and Control and manufacturing to ensure a smooth technology transfer to Lonza for our FasTCAR-enabled product candidate GC012F. We plan to build on the momentum achieved during the first quarter with several near-term catalysts expected during 2021. As we continue to ramp up clinical development efforts, we continue to expand our team in the U.S. and preparing to expand our GMP manufacturing facility in China. We also look forward to providing updates at the ASCO and EHA 2021 annual meetings on the FasTCAR-enabled BCMA/CD19 dual-targeting candidate GC012F for the treatment of r/r multiple myeloma, which has demonstrated fast, deep, and durable responses in a predominantly high-risk multiple myeloma patient population. We are excited to begin collaborating with Lonza to manufacture our FasTCAR-enabled product candidate GC012F as we work towards the U.S. IND filing in the first half of 2022. We believe the potential of our proprietary FasTCAR and TruUCAR platforms is vast, and we are working expeditiously to bring new product candidates into clinical development," Dr. Cao concluded.